当前位置: 首页 >> 检索结果
共有 129975 条符合本次的查询结果, 用时 1.4037235 秒

181. Improved hypertension care requires measurement and management in health facilities, not mass screening.

作者: Thomas R Frieden.;Renu Garg.;Andrew E Moran.;Paul K Whelton.
来源: Lancet. 2025年405卷10492期1879-1882页
Improved hypertension control can save millions of lives, but mass hypertension screening, a commonly used approach, is a barrier to progress. Although politically appealing, mass screening diverts resources from improving services in primary health care. Hypertension treatment requires ongoing, long-term care. Mass screening is inefficient: many people with hypertension are not screened or not screened accurately; most people referred do not follow up; many who do follow up are found not to have hypertension; and among those who have hypertension, few initiate and adhere to treatment. Universal measurement of blood pressure among all adults attending health facilities is much more effective and facilitates treatment and ongoing care. Universal facility-based screening can improve diagnosis and control substantially, including among underserved populations. Implementing this approach requires that facilities have validated blood pressure monitors, routinely screen at least all patients aged 30 years and older, and increase the number and proportion of patients being treated for hypertension whose blood pressure is at target (eg, <140/90 mm Hg). The only way to control hypertension is to strengthen facility-based detection and treatment. To prevent heart attacks, strokes, death, and other complications of untreated and inadequately treated hypertension, countries should track and steadily increase the outcome that matters: the number of patients on treatment whose blood pressure is controlled.

182. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

作者: Ashish Sarraju.;Danielle Brennan.;Kierstyn Hayden.;Amanda Stronczek.;Anne C Goldberg.;Erin D Michos.;Darren K McGuire.;Denise Mason.;Grace Tercek.;Stephen J Nicholls.;Douglas Kling.;Annie L Neild.;John Kastelein.;Michael Davidson.;Marc Ditmarsch.;Steven E Nissen.
来源: Lancet. 2025年405卷10491期1757-1768页
Reducing LDL cholesterol prevents atherosclerotic cardiovascular disease (ASCVD) events. The aim of this study was to evaluate the LDL cholesterol-lowering efficacy of a fixed-dose combination (FDC) of obicetrapib, a CETP inhibitor, and ezetimibe.

183. Obicetrapib-ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease.

作者: Seung-Jun Lee.;Byeong-Keuk Kim.
来源: Lancet. 2025年405卷10491期1720-1721页

184. Prevalence of sexual violence against children and age at first exposure: a global analysis by location, age, and sex (1990-2023).

作者: Jack Cagney.;Cory Spencer.;Luisa Flor.;Molly Herbert.;Mariam Khalil.;Erin O'Connell.;Erin Mullany.;Flavia Bustreo.;Joht Singh Chandan.;Nicholas Metheny.;Felicia Knaul.;Emmanuela Gakidou.
来源: Lancet. 2025年405卷10492期1817-1836页
Measuring sexual violence against children (SVAC) is vital to prevention and advocacy efforts, yet existing prevalence studies present estimates for few countries. Here we estimate the prevalence of SVAC for 204 countries by age and sex, from 1990 to 2023, and also report the age at which young survivors of lifetime sexual violence first experienced sexual violence.

185. Innovative strategies to enhance access to HCV therapy.

作者: Hannah Roth.;Andrew Aronsohn.
来源: Lancet. 2025年405卷10491期1722-1723页

186. Mapping the unseen: global prevalence of childhood sexual violence.

作者: Elizabeth J Letourneau.;Luciana C Assini-Meytin.
来源: Lancet. 2025年405卷10492期1792-1793页

187. Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

作者: Graham S Cooke.;Le Manh Hung.;Barnaby Flower.;Leanne McCabe.;Vu Thi Kim Hang.;Vo Thi Thu.;Dang Trong Thuan.;Nguyen Thanh Dung.;Le Thanh Phuong.;Dao Bach Khoa.;Nguyen Thi Chau An.;Pham Ngoc Thach.;Vu Thi Thu Huong.;Dang Thi Bich.;Nguyen Kim Tuyen.;M Azim Ansari.;Chau Le Ngoc.;Vo Minh Quang.;Nguyen Thi Ngoc Phuong.;Le Thi Thao.;Nguyen Bao Tran.;Evelyne Kestelyn.;Cherry Kingsley.;Rogier Van Doorn.;Motiur Rahman.;Sarah L Pett.;Guy E Thwaites.;Eleanor Barnes.;Jeremy N Day.;Nguyen Van Vinh Chau.;A Sarah Walker.
来源: Lancet. 2025年405卷10491期1769-1780页
WHO recommends treating hepatitis C infection with one of three antiviral combinations for 8-12 weeks. No randomised trials have compared these regimens, and high cure rates might be achievable with shorter durations of therapy. We aimed to compare sofosbuvir-daclatasvir with sofosbuvir-velpatasvir, and to evaluate potential novel treatment strategies.

189. The UK Supreme Court's ruling and the rights of transgender people.

作者: Joe Herbert.
来源: Lancet. 2025年405卷10491期1735页

190. The regulatory rollercoaster continues-EMA refuses donanemab.

作者: Bart De Strooper.;Christian Haass.;John Hardy.;Henrik Zetterberg.
来源: Lancet. 2025年405卷10492期1810-1812页

191. The Global North is increasingly unsafe for global health meetings.

作者: Shashika Bandara.;Nhial Deng.;Madhukar Pai.
来源: Lancet. 2025年405卷10491期1728-1730页

192. The death of Pope Francis and his global health legacy.

作者: Howard Lopes Ribeiro.
来源: Lancet. 2025年405卷10491期1735-1736页

193. Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.

作者: Jason Gardosi.;Lauren Jade Ewington.;Katie Booth.;Debra Bick.;George Bouliotis.;Emily Butler.;Sanjeev Deshpande.;Hanna Ellson.;Joanne Fisher.;Adam Gornall.;Ranjit Lall.;Hema Mistry.;Seyran Naghdi.;Stavros Petrou.;Anne-Marie Slowther.;Sara Wood.;Martin Underwood.;Siobhan Quenby.
来源: Lancet. 2025年405卷10491期1743-1756页
The benefits and harms of early induction of labour to reduce shoulder dystocia in fetuses suspected to be large for gestational age (LGA) are uncertain. We aimed to investigate whether early induction of labour is associated with a reduced risk of shoulder dystocia compared with standard care.

194. The challenge of shoulder dystocia prevention and the Big Baby trial.

作者: Christina M Scifres.;Erin M Cleary.
来源: Lancet. 2025年405卷10491期1718-1719页

195. Gastric cancer.

作者: Raghav Sundar.;Izuma Nakayama.;Sheraz R Markar.;Kohei Shitara.;Hanneke W M van Laarhoven.;Yelena Y Janjigian.;Elizabeth C Smyth.
来源: Lancet. 2025年405卷10494期2087-2102页
Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than 650 000 deaths. Epidemiologically, gastric cancer shows substantial geographical variation in incidence, with higher rates in Asia, South America, and eastern Europe, and a rapid increase in early-onset cases among people younger than 50 years. Key risk factors for gastric cancer include Helicobacter pylori infection, diet, obesity, smoking, and genetic predisposition. Early detection through comprehensive diagnostic procedures is crucial for optimising treatment outcomes. Standard treatment approaches for locally advanced gastric cancer include surgical resection, particularly D2 lymphadenectomy, complemented by chemotherapy and radiotherapy. There is increasing implementation of minimally invasive surgical techniques for operable disease and integration of immune checkpoint inhibitors and targeted therapies for advanced stages. Emerging therapies, such as novel targeted treatments and next-generation immunotherapies, show promise in improving survival and quality of life. Future directions in the management of gastric cancer focus on precision medicine, continued advancement in immunotherapy, novel early detection methods, and a multidisciplinary approach to care. These strategies aim to enhance the overall effectiveness of treatment and prognosis worldwide.

196. From disappointment to despair: USAID cuts to Myanmar's HIV services.

作者: Chengshi Shiu.;Jennifer Ho.;Myo Nyein Aung.;Wei-Ti Chen.
来源: Lancet. 2025年405卷10491期1737页

197. Can Somalia avert a food security catastrophe?

作者: Safayet Jamil.;Masoud Mohammadnezhad.;Faisal Muhammad.
来源: Lancet. 2025年405卷10492期1814页

200. Iscalimab 600 mg: justified or excessive?

作者: Yi-Yu Ho.;Hong-Chun Lin.;Chien-Min Lien.;Ming-Jen Wang.;Ching-Mao Chang.
来源: Lancet. 2025年405卷10489期1578页
共有 129975 条符合本次的查询结果, 用时 1.4037235 秒